Alderley Park, UK – January 2026 – ImmunoKey, a UK-based biotechnology company developing a next-generation CAR T-cell platform for solid tumours, is is pleased to announce the appointment of two internationally recognised leaders in T-cell immunotherapy, Professor Phil Darcy and Dr. David Gilham, to its Scientific Advisory Board (SAB).

Professor Phil Darcy, Ph.D., brings over two decades of pioneering research in engineered T-cell therapies. Based at the Peter MacCallum Cancer Centre, where he co-heads the Cancer Immunology Program, Professor Darcy led Australia's first CAR-T clinical trial and has published over 200 papers with more than 26,000 citations. His expertise spans CAR design, T-cell persistence, and the application of adoptive cell therapies in both haematological and solid tumour indications.

Dr. David Gilham, Ph.D., is a globally respected expert in T-cell engineering, with a track record in developing and translating novel CAR-T and allogeneic cell therapies. Formerly Chief Scientific Officer at Celyad Oncology and academic lead at the University of Manchester’s Clinical and Experimental Immunotherapy Group, Dr. Gilham has played a pivotal role in advancing multiple cell therapy candidates into early-phase clinical trials.

These appointments significantly bolster ImmunoKey’s translational and clinical development capabilities as the company advances its CARKey™ platform toward clinical validation in ovarian cancer.

Gray Kueberuwa, CEO of ImmunoKey, commented:

“Phil and Dave bring unparalleled insight into the design, optimisation, and clinical translation of CAR-T therapies. Their contributions will be instrumental as we progress from platform validation to IND-enabling studies for our lead programme in ovarian cancer”

With these new advisory board members, ImmunoKey brings world-class scientific guidance to accelerate the development of effective CAR T-cell treatments to deliver life-changing therapies for patients with solid tumours.

About ImmunoKey
ImmunoKey Ltd. is a UK-based biotechnology company developing next-generation CAR T-cell therapies to overcome the barriers of treating solid tumours. The company's proprietary CARKey™ platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies AmpliT™ and ReviT™ to enhance T-cell persistence and function in the tumour microenvironment. Backed by a leadership team with proven success in cell therapy development and clinical translation, ImmunoKey is advancing a pipeline of novel immunotherapies to address critical unmet needs in oncology.

For more information, visit www.immunokey.co.uk.

For media inquiries, please contact:

ImmunoKey Ltd: Dr. Gray Kueberuwa
Email: Info@immunokey.co.uk
Website: www.immunokey.co.uk